| # | Drug | Count |
|---|---|---|
| 0 | NIVOLUMAB | 168 |
| 1 | IPILIMUMAB | 104 |
| 2 | CARBOPLATIN | 76 |
| 3 | PACLITAXEL | 57 |
| 4 | CISPLATIN | 34 |
| 5 | BEVACIZUMAB | 29 |
| 6 | DURVALUMAB | 24 |
| 7 | METHYLPREDNISOLONE | 18 |
| 8 | PEMETREXED DISODIUM | 18 |
| 9 | ETOPOSIDE | 17 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | BEVACIZUMAB-MALY | 2 | 0.0100 |
| 1 | NITAZOXANIDE | 1 | 0.0029 |
| 2 | IPILIMUMAB | 104 | 0.0024 |
| 3 | CEMIPLIMAB-RWLC | 4 | 0.0019 |
| 4 | SENNOSIDES A AND B | 3 | 0.0018 |
| 5 | NIVOLUMAB | 168 | 0.0017 |
| 6 | TREMELIMUMAB | 7 | 0.0016 |
| 7 | VONOPRAZAN FUMARATE | 10 | 0.0012 |
| 8 | NALDEMEDINE | 2 | 0.0012 |
| 9 | DURVALUMAB | 24 | 0.0011 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | CTLA-4-directed Blocking Antibody [EPC] | 111 | 0.0023 |
| 1 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 168 | 0.0017 |
| 2 | Programmed Death Ligand-1 Blocker [EPC] | 24 | 0.0011 |
| 3 | Platinum-based Drug [EPC] | 115 | 0.0004 |
| 4 | Reducing and Complexing Thiol [EPC] | 1 | 0.0004 |
| 5 | Microtubule Inhibitor [EPC] | 61 | 0.0004 |
| 6 | Topoisomerase Inhibitor [EPC] | 17 | 0.0002 |
| 7 | Vasopressin V2 Receptor Antagonist [EPC] | 3 | 0.0002 |
| 8 | Antiprotozoal [EPC] | 2 | 0.0002 |
| 9 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 31 | 0.0002 |